An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock

Critical Care Medicine

Volumn 27, Issue 5, 1999, Pages 913-922

  Grover, Robert ^a   Zaccardelli, David ^a   Colice, Gene ^a   Guntupalli, Kalpalatha ^b   Watson, David ^c   Vincent, Jean Louis ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BEN TAUB GENERAL HOSPITAL   (United States)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d ERASME HOSPITAL   (Belgium)

Author keywords

Dobutamine; Dose escalation; Human; N(G) methyl L arginine hydrochloride; Nitrate; Nitric oxide; Nitric oxide synthase inhibitor; Norepinephrine; Open label; Septic shock; Severe sepsis

Indexed keywords

DOBUTAMINE; N(G) METHYLARGININE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; OXYGEN;

ADULT; AGED; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; HEART INDEX; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0032990946     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199905000-00025     Document Type: Article

References (52)

1. 1. Rees DD, Palmer RMJ, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-3378
2. 2. Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii:997-1000
3. 3. Haynes WG, Noon JP, Walker BR, et al: Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993; 11:1375-1380
4. 4. Stamler JS, Loh E, Roddy M, et al: Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89:2035-2040
5. 5. Palmer RMJ, Ashton DS, Moncada S: Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature 1988; 333:664-666
6. 6. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012
7. 7. Rees DD: Role of nitric oxide in the vascular dysfunction of septic shock. Biochem Soc Trans 1995; 23:1025-1029
8. 8. Rees DD, Cellek S, Palmer RMJ, et al: Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 1990; 173:541-547
9. 9. MacNaul KL, Hutchinson NI: Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 1993; 196:1330-1334
10. 10. Snell RJ, Parrillo JE: Cardiovascular dysfunction in septic shock. Chest 1991; 99:1000-1009
11. 11. Julou-Schaeffer G, Gray GA, Fleming I, et al: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990; 259:H1038-H1043
12. 12. Laszlo F, Whittle BJR, Moncada S: Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br J Pharmacol 1994;111:1309-1315
13. 13. Stadler J, Billiar TR, Curran RD, et al: Effect of exogenous and endogenous nitric oxide on mitochondrial respiration of rat hepatocytes. Am J Physiol 1991; 260:C910-C916
14. 14. Brown GC: Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995; 369:136-139
15. 15. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477
16. 16. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-436
17. 17. Fisher CJ, Dhainaut JA, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271:1836-1843
18. 18. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23:994-1006
19. 19. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA 1995; 273:934-941
20. 20. Fisher CJ, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor.Fc fusion protein. TV Engl J Med 1996; 334: 1697-1702
21. 21. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-742
22. 22. Opal S, Fisher CJ, Dhainaut J-FA, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25:1115-1124
23. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990; 172:1132-1138
24. 24. Meyer J, Traber L, Nelson S, et al: Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 1992; 73:324-328
25. 25. Rees DD, Monkhouse JE, Cambridge D, et al: Nitric oxide and the haemodynamic profile of endotoxin shock in the conscious mouse. Br J Pharmacol 1998; 124:540-546
26. G-monomethyl-L-arginine HC1 (L-NMMA: 546C88) improves survival in a conscious instrumented mouse model of endotoxic shock. Endothelium 1995; 3(Suppl):S116
27. 27. Redl H, Schlag G, Gasser H, et al: Treatment with the NO synthase inhibitor 546C88 twelve hours after start of E. coli bacteremia is beneficial in a baboon model of septic shock. Shock 1997; 8(Suppl 1):51
28. 28. Schmidt K, Klatt P, Mayer B: Characterisation of endothelial cell amino acid transport systems involved in the actions of nitric oxide synthase inhibitors. Mol Pharmacol 1993; 44:615-621
29. G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of nitric oxide synthases? Am J Physiol 1995; 269: C750-C756
30. 30. Petros A, Bennett D, Vallance P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338:1557-1558
31. G-monomethyl-L-arginine, an inhibitor of nitric oxide synthase. Intensive Care Med 1993; 19:227-231
32. G-Monomethyl-L-arginine, an inhibitor of nitric oxide production, reverses interleukin-2 mediated hypotension in humans. Crit Care Med 1995; 23:1018-1024
33. 33. Kelm M, Feelisch M, Grube R, et al: Metabolism of endothelium-derived nitric oxide in human blood. In: The Biology of Nitric Oxide, Part 1. Moncada et al (Eds). London, Portland Press Proceedings, 1992
34. 34. Dykhuizen RS, Copland M, Smith CC, et al: Plasma nitrate concentration and urinary nitrate excretion in patients with gastroenteritis. J Infect 1995; 31:73-75
35. 35. Ochoa JB, Udekwu AO, Billiar TR, et al: Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991; 214:621-626
36. 36. de Werra I, Jaccard C, Corradin S, et al: Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25:607-613
37. 37. Bone RC, Fisher CJ Jr, Clemmer TP, et al: Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17:389-393
38. 38. Leone AM, Francis PL, Rhodes P, et al: A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem Biophys Res Commun 1994; 200:951-957
39. 39. Zapol WM, Snider MT: Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 1997; 296: 476-480
40. 40. Martin C, Papazian L, Perrin G, et al: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826-1831
41. 41. Finkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
42. 42. Brady AJB, Poole-Wilson PA, Harding SE, et al: Nitric oxide production within cardiac myocytes reduces their contractility in endotoxaemia. Am J Physiol 1992; 263:H1963-H1966
43. 43. Hare JM, Loh E, Creager MA, et al: Nitric oxide inhibits the positive inotropic response to β-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995; 92: 2198-2203
44. 44. Archer SL, Tolins JP, Raij L, et al: Hypoxie pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor. Biochem Biophys Res Commun 1989; 164:1198-1205
45. 45. Petros A, Lamb G, Leone A, et al: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-39
46. 46. Takala J, Guntupalli K, Donaldson J, et al: Multicentre, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88 in patients with septic shock: effect on early noncardiovascular organ function. Intensive Care Med 1997; 23(Suppl 1):S51
47. 47. Lingnau W, McGuire R, Dehring D, et al: Changes in regional hemodynamics after nitric oxide synthase inhibition during ovine bacteremia. Am J Physiol 1996; 270:R207-R216
48. 48. Harbrecht BG, Billiar TR, Stadier J, et al: Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia. Crit Care Med 1992; 20:1568-1574
49. 49. Pastor C, Teisseire B, Vicaut E, et al: Effects of L-arginine and L-nitro-arginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model. Crit Care Med 1994; 22:465-469
50. 50. Grover R, Bakker J, McLuckie A, et al: The nitric oxide synthase inhibitor 546C88 promotes the resolution of shock in patients with severe sepsis. Crit Care Med 1998; 26(Suppl):A29
51. 51. Le Gall J-R, Lemeshow S, Saulnier F: A new simplified acute physiology score (SAPS II) based on a North American multicenter study. JAMA 1993; 270: 2957-2963
52. 52. Le Gall J-R, Lemeshow S, Leleu G, et al: Customized probability models for early severe sepsis in adult intensive care patients. JAMA 1995; 273: 644-650